Form 4: Entrada Therapeutics CFO Kory James Wentworth Exercises Stock Options
SEC Form 4 Filing
Kory James Wentworth, CFO of Entrada Therapeutics, exercised options to acquire 9,000 shares of common stock at $2.10 per share on March 15, 2024.
Summary
- On March 15, 2024, Kory James Wentworth, the Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA), exercised stock options to purchase 9,000 shares of common stock at a price of $2.10 per share.
- Following this transaction, Wentworth directly owns 83,170 shares of common stock.
- Wentworth also holds 43,157 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option exercise. It doesn't inherently indicate positive or negative sentiment, but rather reflects a standard part of executive compensation.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the issuance of new shares, potentially diluting existing ownership slightly.
Key Dates
| Date | Description |
|---|---|
| 11/16/2021 | 25% of the shares subject to the option vested and became exercisable. |
| 03/15/2024 | CFO Kory James Wentworth exercised stock options. |
| 03/19/2024 | Date of signature on the Form 4 filing. |
| 11/10/2030 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.